{"id":1013023,"date":"2026-10-23T04:06:56","date_gmt":"2026-10-23T08:06:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/phase-iii-trial-shows-veracytes-decipher-prostate-test-can-predict-benefit-from-adding-abiraterone-to-treatment-in-very-high-risk-prostate-cancer\/"},"modified":"2026-10-23T04:06:56","modified_gmt":"2026-10-23T08:06:56","slug":"phase-iii-trial-shows-veracytes-decipher-prostate-test-can-predict-benefit-from-adding-abiraterone-to-treatment-in-very-high-risk-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/phase-iii-trial-shows-veracytes-decipher-prostate-test-can-predict-benefit-from-adding-abiraterone-to-treatment-in-very-high-risk-prostate-cancer\/","title":{"rendered":"Phase III Trial Shows Veracyte\u2019s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer"},"content":{"rendered":"

\nSTAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its Decipher\u00ae Prostate Genomic Classifier can predict benefit from adding abiraterone to androgen deprivation therapy (ADT) in men with clinically very high-risk nonmetastatic prostate cancer. The findings will be presented tomorrow in a proffered paper oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 by Dr. Sarah Howlett of University College London (UCL).<\/p>\n

The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This predictive evidence bolsters Decipher\u2019s high-risk claims to help physicians identify which patients are most likely to benefit from adding abiraterone to ADT. These findings build on Decipher\u2019s long-established standing in guidelines for assessing the risk of cancer progression, as well as prior STAMPEDE analysis that was recently incorporated into the NCCN 2027 prostate cancer guidelines for high- and very high-risk disease.<\/p>\n

For patients with very high-risk disease, the decision to add abiraterone treatment carries significant consequences. Abiraterone can improve cancer outcomes when added to ADT but also adds side effects and treatment burden. Understanding a patient\u2019s expected benefit from the additional treatment can help physicians and patients weigh the potential benefit alongside the impact on daily life.<\/p>\n

\u201cFor men with very high-risk disease, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,\u201d said Dr. Sarah Howlett, clinical research fellow in the Research Department of Oncology at UCL and the study\u2019s presenter. \u201cThis analysis shows that the Decipher test can identify which patients in this study population were at greatest risk of prostate cancer-specific mortality and, therefore, may gain the greatest benefit from adding abiraterone to ADT. That gives physicians and patients evidence to make more confident treatment decisions based on the biology of the individual tumor.\u201d<\/p>\n

\n Key study findings in very high-risk patients:<\/strong>\n <\/p>\n